LMNL News and Press, Liminal Biosciences Inc From 04/05/23

2023-04-05 10:21:14 ET Nanocap biotech Liminal BioSciences ( NASDAQ: LMNL ) added ~77% in the morning hours Wednesday after announcing an unsolicited non-binding proposal from Structured Alpha LP to obtain the full ownership of the company for $7.50 per share in cash. Stru...

2023-04-05 10:07:20 ET Gainers: Liminal BioSciences ( LMNL ) +81% . InflaRx ( IFRX ) +51% . 180 Life Sciences ( ATNF ) +26% . YS Biopharma ( YS ) +22% . Immunic ( IMUX ) +21% . Losers: Bullfrog AI ( BFRG ) -15% .&#...

Liminal Biosciences Confirms Receipt of Unsolicited Non-Binding Transaction Proposal PR Newswire LAVAL , QC and CAMBRIDGE, England , April 5, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), ...

THOMVEST SUBMITS PROPOSAL TO ACQUIRE LIMINAL BIOSCIENCES ON AN ALL CASH BASIS Canada NewsWire TORONTO , April 5, 2023 /CNW/ - Thomvest Asset Management Ltd. (" Thomvest ") today announced that it has made a non-binding, all cash proposal (the " Proposal "...

2023-03-17 16:08:04 ET Liminal BioSciences Inc. (LMNL) Q4 2022 Results Conference Call March 16, 2023 08:30 AM ET Company Participants Shrinal Inamdar - IR Bruce Pritchard - CEO Nicole Rusaw - CFO Conference Call Participants Antonia Borovina - Bloom ...

2023-03-15 16:49:16 ET Liminal BioSciences press release ( NASDAQ: LMNL ): Q4 net loss of $4.2M. For further details see: Liminal BioSciences reports Q4 results

Liminal BioSciences Reports Fourth Quarter and Year Ended 2022 Financial Results Canada NewsWire CTA-enabling work on track to seek approval to commence Phase 1 clinical trial of LMNL6511 during the second half of 2023 Addition of GPR40 agonist discovery program aimi...

Liminal BioSciences to Report Fourth Quarter and Year Ended 2022 Financial Results on March 15, 2023 Canada NewsWire LAVAL, QC , and CAMBRIDGE, England , March 13, 2023 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), ...

Liminal BioSciences ( NASDAQ: LMNL ) receives Nasdaq notice as the stock has regained compliance with Nasdaq listing requirement. The bid price has been $1.00 per share or greater for at least ten consecutive business days, from February 1, 2023 through February 14, 2023. Stoc...

Liminal BioSciences Regains Compliance with NASDAQ Minimum Bid Price Requirement Canada NewsWire LAVAL, QC , Feb. 15, 2023 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that it has received written notice from...